Gene · 57650
CIP2A: cellular inhibitor of PP2A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CIP2A: cellular inhibitor of PP2A. Genes, record 57650. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/57650
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q8TCG1 | Protein CIP2A | 905 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59635 | Q8TCG1 | Espacenet |
| WO 2025259899 A1 | 2025-12-18 | 3 | Q8TCG1 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3643 | Q8TCG1 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3240 | Q8TCG1 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4729 | Q8TCG1 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2291 | Q8TCG1 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2291 | Q8TCG1 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3240 | Q8TCG1 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3643 | Q8TCG1 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4729 | Q8TCG1 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants663
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CIP2A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 4 | 2025 |
| P30CA069533 | OHSU Knight Cancer Institute | 4 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA138313 | Medical University of South Carolina - Cancer Center Support Grant | 3 | 2025 |
| T32CA229102 | Surgical Oncology Research Training Program | 3 | 2025 |
| T32DE017551 | T-COHR: Training in Craniofacial and Oral Health Research | 3 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 2 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
1 to 10 of 663Source NIH's project files
See all 663 nih grantsPapers1,316
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DDIAS shields vulnerable single-stranded DNA to direct neurogenesis and protect cancer cells. | Mol Cell | 2026 | 42822412 | PubTator, text mining | PubMed |
| Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1. | medRxiv | 2026 | 42818163 | PubTator, text mining | PubMed |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | 42704219 | PubTator, text mining | PubMed |
| Dynamic chromatin tethering of MDC1 regulates genome stability. | Nucleic Acids Res | 2026 | 42703974 | PubTator, text mining | PubMed |
| MAD2B guides chromosome stability in mitosis via the MAD2B-CIP2A signaling axis. | J Mol Cell Biol | 2026 | 42667364 | PubTator, text mining | PubMed |
| DDIAS shields single-stranded DNA in mitosis and promotes vertebrate brain development. | Cell | 2026 | 42636811 | PubTator, text mining | PubMed |
| Mitotic single-stranded DNA suppression by DDIAS. | Mol Cell | 2026 | 42636809 | PubTator, text mining | PubMed |
| Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. | Sci Adv | 2026 | 42555732 | PubTator, text mining | PubMed |
| CIP2A-TOPBP1 complex and PP2A dynamically regulate Polθ recruitment and phosphorylation at mitotic DNA double-strand breaks. | Proc Natl Acad Sci U S A | 2026 | 42546199 | PubTator, text mining | PubMed |
| PP2A: Decoding Its Structure, Regulation and Therapeutic Applications in Neurological Disorders. | Curr Neuropharmacol | 2026 | 42522313 | PubTator, text mining | PubMed |
1 to 10 of 1,316
See all 1,316 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/57650
GET https://conductscience.org/api/genes/v1/57650/patents?page=2